Patients' opinions of olanzapine and risperidone following long-term treatment: Results from a cross-sectional survey

Pharmacopsychiatry

Volumn 38, Issue 4, 2005, Pages 147-157

  McGrath, Brent M ^a   Tempier, R P ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; OLANZAPINE; RISPERIDONE; TRANQUILIZER;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG TOLERABILITY; FAMILY LIFE; FEMALE; HEALTH STATUS; HUMAN; LONG TERM CARE; MALE; MENTAL HEALTH SERVICE; PATIENT ATTITUDE; PATIENT SATISFACTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECREATION; SCHIZOPHRENIA; SELF REPORT; SEXUAL BEHAVIOR; SOCIAL INTERACTION; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WELLBEING;

ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; ATTITUDE; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; FAMILY RELATIONS; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEXUAL BEHAVIOR;

EID: 23044432968     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-871236     Document Type: Article

References (64)

1. Al-Zakwani IS, Barren JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of Healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003; 19 (7): 619-626
2. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19 (3): 609-618
3. Awad AG. Antipsychotic medications in schizophrenia: how satisfied are our patients? In: Clear perspectives - management issues in schizophrenia: patient satisfaction, compliance and outcomes in schizophrenia London (UK): AstraZeneca Pharmaceuticals, 1999: 1-6
4. Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 85-588
5. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994; 89(Suppl.380): 27-32
6. Awad AG, Hogan TP, Voruganti LNP, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 (Suppl. 3): 123-132
7. Awad AG, Lapierre YD, Angus C, Rylander A, and The Canadian Remoxipride Group. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. J Psychiatry Neurosci 1997; 22 (4): 244-248
8. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Can J Psychiatry 2004; 49 (5): 283-284
9. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 1997; 6: 21-26
10. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676
11. Bartko G, Herczeg I, Bekesy M. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J Clin Psychiatry 1987; 48: 363-365
12. Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19 (8): 787-805
13. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia. Effects of second generation antipsychotics. CNS Drugs 2002; 16 (7): 473-484
14. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53 (12): 142-1145
15. Franz M, Lis K, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170: 422-425
16. Click ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical and conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol 2002; 17 (2): 65-68
17. Guy W. (editor). AIMS, in ECDEU Assessment Manual. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976: pp. 534-537
18. Hamilton SH, Revicki DA, Edgel L, Genduso LA, Tollefson GD. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia - results from a randomized clinical trial. Pharmacoeconomics 1999; 15: 469-480
19. Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002; 16 (7): 457-471
20. Hertling I, Philipp M, Dvorak A, Glaser T, Mast O, Beneke M, Ramskogler K, Saletu-Zyhlarz G, Walter H, Lesch OM. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 2003; 47 (1): 37-46
21. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347-352
22. Hogan TP, Awad AG, Eastwood MR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177-183
23. Jacovljevic M, Dossenbach MR, Friedel P, Schausberger B, Grundy SL, Hotujac L, Folnegovic-Smalc V, Uglesic B, Tollefson G. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia. Psychiatr Danub 1999; 11: 3-11
24. Jarema M, Murawiec S, Szafranski T, Szaniawska A, Konieczynska Z. Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs. Psychiatr Pol 2001; 35(1): 5-19
25. Kanter J. Clinical case management: definition, principles, components. Hosp Community Psychiatry 1989; 40: 361-368
26. Karagianis JL, LeDrew KK, Walker DJ. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. Curr Med Res Opin 2003; 19: 473-480
27. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162: 3-10
28. Kim K, Pae C, Chae J, Bank W, Jun T, Kim D et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63 (5): 408-413
29. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996; 93: 381-388
30. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trail of olanzapine versus haloperidol. Am J Psychiatry 2003; 160 (8): 1396-1404
31. Llorca PM, Chereau I, Bayle FJ, Lancon C. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002; 17: 129-138
32. May PRA, Van Putten T, Yale C, Potepan P, Jenden DJ, Fairchild MD et al. predicting individual response to drug treatment in schizophrenia: a test dose model. J Ner Ment Dis 1976; 162 (3): 177-183
33. McGrath BM, Tempier RP. Cross-sectional analysis of medication prescriptions for a continuing care patient population using the psychiatry quality measurement. Presented at the 9th Congress of the International Federation of Psychiatric Epidemiology, Edmonton, Alberta, Canada: May 2002
34. McGrath BM, Tempier RP. Implementing quality management in psychiatry: from theory to practice - shifting focus from process to outcome. Can J Psychiatry 2003; 48 (7): 467-474
35. Moritz S, Woodward TS, Krausz M, Naber D, and the PERSIST Study Group. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. Int Clin Psychopharmacol 2002; 17: 41-44
36. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 (Suppl.3): 133-138
37. Naber D, Moritz S, Lambert M, Pajonk F, Holzbach R, Mass R et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79-88
38. Naber D, Walther A, Kircher T, Hayek D, Holzbach R. Subjective effects of neuroleptic predict compliance. In Gaebel W, Ward AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods Vienna: Springer-Verlag, 1994: pp. 85-98
39. Patel NC, Dorson PG, Edwards N, Mendelson S, Crismon ML. One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 2002; 53 (7): 891-893
40. Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997; 95: 464-468
41. Puri BK. SPSS in practice: an illustrated guide; 2nd Edition New York: Oxford University Press, Inc, 2002: pp. 1-175
42. Rabinowitz J, Bromet EJ, Davidson M. Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. Schizophr Bull 2001; 27 (4): 597-600
43. Ritsner M, Perelroyzen G, Ilan H, Gibel A. Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004; 24 (3): 245-254
44. Sacristan JA, Gomez JC, Montejo AL, Vieta E, Gregor KJ, and the EFESO Study Group. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. Clin Ther 2000; 22 (5): 583-599
45. Sarwer-Foner GJ. The role of neuroleptic medication in psychotherapeutic interaction. Compr Psychiatry 1960; 1: 291-300
46. Sarwer-Foner GJ. On the mechanisms of action of neuroleptic drugs: a theoretical psychodynamic explanation. Recent Adv Biol Psychiatry 1963; 6: 217-232
47. Schillevoort I, de Boer A, Herings RMC, Roos RAC. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother 2001; 35: 1517-1522
48. Stokes ME, Davis CS, Koch GG. Categorical data analysis using The SAS System; 2nd Edition North Carolina: SAS Institute, 2000: pp. 626
49. Strauss JS. Subjective experiences of schizophrenia: toward a new dynamic psychiatry-II. Schizophr Bull 1989; 15 (2): 177-187
50. Tempier R. Quality of life and schizophrenia: the impact of novel antipsychotic medications. Can Psychiatr Assoc Bull 1999; 31 (5): 144-146
51. Tomb DA. Psychiatry. 6th edition. Philadelphia: Lippincott Williams & Wilkins, 1999: pp. 19-39
52. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 447-480
53. Van Putten T, May PRA, Marder SR. Subjective responses to thiothixene and chlorpromazine. Psychopharmacol Bull 1980; 16 (3): 36-38
54. Van Putten T, May PRA, Marder SR. Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 1984; 141 (1): 16-19
55. Van Putten T, May PRA, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190
56. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-262
57. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacol 2004; 171: 121-132
58. Voruganti LNP, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135-145
59. Watanabe A, Shibata I, Kato T. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Psychiatry Clin Neurosci 2004; 58: 268-273
60. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57 (Suppl. 11): 53-60
61. Williams B. Patient satisfaction: a valid concept? Soc Sci Med 1994; 38 (4): 509-516
62. Windgassen K. Treatment with neuroleptics: the patient's perspective. Acta Psychiatr Scand 1992; 86: 405-410
63. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64 (6): 663-667
64. Ziegler DM, Peachey TJ. A study of treatment outcomes from atypical antipsychotic medications in the Virginia public system of community care. Community Ment Health J 2003; 39 (2): 169-182